Rising incidence and demographics of hepatocellular carcinoma in the USA: what does it mean?

2011 ◽  
Vol 5 (3) ◽  
pp. 365-370 ◽  
Author(s):  
Joshua J Shaw ◽  
Shimul A Shah
Keyword(s):  
Hepatocellular Carcinoma ◽  
The Usa ◽  
Rising Incidence

Cohort Contributions to Race- and Gender-Specific Trends in the Incidence of Hepatocellular Carcinoma in the USA

2017 ◽  
Vol 42 (3) ◽  
pp. 835-840 ◽  
Author(s):  
Eliza W. Beal ◽  
Dmitry Tumin ◽  
Ali Kabir ◽  
Dimitrios Moris ◽  
Xu-Feng Zhang ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Race And Gender ◽  
The Usa ◽  
And Gender ◽  
Gender Specific

Rising incidence of diabetes mellitus in youth in the USA

2017 ◽  
Vol 13 (7) ◽  
pp. 379-380 ◽  
Author(s):  
Paul Zimmet ◽  
Jonathan Shaw
Keyword(s):  
Diabetes Mellitus ◽  
The Usa ◽  
Rising Incidence

Impact of immigration in presentation and outcomes of hepatocellular carcinoma in the USA

2019 ◽  
Vol 31 (1) ◽  
pp. 24-28 ◽  
Author(s):  
Ashraf A. Ashhab ◽  
Holly Rodin ◽  
Jesse Powell ◽  
Jose D. Debes
Keyword(s):  
Hepatocellular Carcinoma ◽  
The Usa

Rising incidence of hepatocellular carcinoma in a Spanish health area between 2008 and 2016

2017 ◽  
Vol 66 (1) ◽  
pp. S206
Author(s):  
A. Lue ◽  
S. Lorente ◽  
E. Martinez ◽  
J. Nerin ◽  
E. Solanas ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Health Area ◽  
Rising Incidence ◽  
Spanish Health

scholarly journals Treatment of inoperable hepatocellular carcinoma with immunotherapy

2019 ◽  
Vol 12 (7) ◽  
pp. e229744 ◽  
Author(s):  
Sean P Tighe ◽  
Umair Iqbal ◽  
Christopher T Fernandes ◽  
Aijaz Ahmed
Keyword(s):  
Hepatocellular Carcinoma ◽  
Clinical Presentation ◽  
Treatment Options ◽  
Linkage To Care ◽  
Experimental Treatment ◽  
Hepatitis C Virus Infection ◽  
Chronic Liver Diseases ◽  
The Third ◽  
The Usa ◽  
High Risk Populations

In the USA, mortality associated with hepatocellular carcinoma (HCC) continues to rise. Globally, HCC is the third most common cause of cancer-related death. In early stages of HCC, hepatic resection or liver transplantation are the preferred treatment options with a high probability of recurrence-free postoperative course. However, ineffective screening of chronic liver diseases in high-risk populations, poor linkage to care and suboptimal HCC surveillance has led to increasing rates of late-stage HCC at clinical presentation or diagnosis amenable only to palliative and experimental treatment options. Our case is a 66-year-old man with chronic hepatitis C virus infection complicated by cirrhosis and inoperable HCC which was non-responsive to selective intrahepatic trans-arterial chemoembolisation by interventional radiology. Therefore, he was treated with nivolumab immunotherapy and demonstrated normalisation of previously elevated alpha-fetoprotein levels suggestive of at least a partial response to immunotherapy. No adverse events related to nivolumab immunotherapy were encountered.

scholarly journals Racial and Sex Disparities in Hepatocellular Carcinoma in the USA

2020 ◽  
Vol 19 (4) ◽  
pp. 462-469
Author(s):  
Faith Ajayi ◽  
Jenny Jan ◽  
Amit G. Singal ◽  
Nicole E. Rich
Keyword(s):  
Hepatocellular Carcinoma ◽  
The Usa ◽  
Sex Disparities

Texas Has the Highest Hepatocellular Carcinoma Incidence Rates in the USA

2020 ◽  
Author(s):  
Hashem B. El-Serag ◽  
Rebecca Sardell ◽  
Aaron P. Thrift ◽  
Fasiha Kanwal ◽  
Paige Miller
Keyword(s):  
Hepatocellular Carcinoma ◽  
Incidence Rates ◽  
The Usa

scholarly journals Epidemiologic, humanistic and economic burden of hepatocellular carcinoma in the USA: a systematic literature review

2020 ◽  
Vol 7 (3) ◽  
pp. HEP27 ◽  
Author(s):  
Abdalla Aly ◽  
Sarah Ronnebaum ◽  
Dipen Patel ◽  
Yunes Doleh ◽  
Fernando Benavente
Keyword(s):  
Quality Of Life ◽  
Hepatocellular Carcinoma ◽  
Economic Burden ◽  
Systemic Treatment ◽  
Advanced Disease ◽  
Poor Quality ◽  
Disease Stage ◽  
The Usa ◽  
Humanistic Burden

Aim: To describe the epidemiologic, humanistic and economic burdens of hepatocellular carcinoma (HCC) in the USA. Materials & methods: Studies describing the epidemiology and economic burden from national cohorts, any economic models, or any humanistic burden studies published 2008–2018 were systematically searched. Results: HCC incidence was 9.5 per 100,000 person-years in most recent data, but was ∼100-times higher among patients with hepatitis/cirrhosis. Approximately a third of patients were diagnosed with advanced disease. Patients with HCC experienced poor quality of life. Direct costs were substantial and varied based on underlying demographics, disease stage and treatment received. Between 25–77% of patients did not receive surgical, locoregional or systemic treatment. Conclusion: Better treatments are needed to extend survival and improve quality of life for patients with HCC.

Sign in / Sign up

Export Citation Format

Share Document